Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$106.44 USD

106.44
1,088,790

-1.65 (-1.53%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $106.33 -0.11 (-0.10%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intuitive Surgical (ISRG) Q1 Earnings, Revenues Lag Estimates

by Zacks Equity Research

Intuitive Surgical's (ISRG) Q1 results outside the United States impress.

Stryker's LIFEPAK CR2 Defibrillator Launch to Boost MedSurg

by Zacks Equity Research

Stryker's (SYK) emergency care department offers a broad range of products and systems.

    Here's Why You Should Buy Masimo (MASI) Stock Right Now

    by Zacks Equity Research

    Masimo (MASI) has been benefitting from developments like the FDA clearance of the Rad-67 Pulse CO-Oximeter.

      Here's Why Investors Should Retain Accuray (ARAY) Stock Now

      by Zacks Equity Research

      Management at Accuray (ARAY) sees significant opportunities in China.

      Here's Why You Should Buy Varian Medical (VAR) Stock Now

      by Zacks Equity Research

      Varian Medical (VAR) announces the installation of cyclotron for its ProBeam proton therapy system at the Hefei Ion Medical Center in China.

      Align Rides on Firm Global Footprint Despite Fierce Rivalry

      by Zacks Equity Research

      Align's (ALGN) solid performance in the Europe, Middle East and Africa and Asia-Pacific geographies is appreciative.

      Here's Why You Should Hold Becton, Dickinson Stock for Now

      by Zacks Equity Research

      Becton, Dickinson (BDX) announces the FDA premarket approval for Venovo venous stent device.

      ABIOMED Impella Data Show Significant Rise in Survival Rates

      by Zacks Equity Research

      ABIOMED (ABMD) plans to expand products like Impella CP, Impella Connect, Impella 5.5 and Impella RP.

      Varian Medical Opens Office in South Africa, Expands in EMEA

      by Zacks Equity Research

      Varian Medical (VAR) sees a slew of developments in the EMEA region of late.

      Here's Why You Should Retain ABIOMED Stock in Your Portfolio

      by Zacks Equity Research

      Despite cutthroat competition in the niche markets, ABIOMED (ABMD) seems to be well-positioned for growth on strong guidance and solid product portfolio.

      Integer Holdings Gets Positive Outlook & B+ Rating From S&P

      by Zacks Equity Research

      Integer (ITGR) strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.

      Why Veeva Systems (VEEV) is an Attractive Pick Right Now?

      by Zacks Equity Research

      Veeva Systems' (VEEV) strong product portfolio is likely to provide it with a competitive edge in the MedTech space.

      Here's Why Investors Should Retain NextGen Healthcare Stock

      by Zacks Equity Research

      Despite aggressive rivalry in the niche space, NextGen (NXGN) will continue to benefit from strong demand for its other NextGen solutions that include Hospitals, EHR and practice management.

      Why Is Masimo (MASI) Up 2.5% Since Last Earnings Report?

      by Zacks Equity Research

      Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Allscripts' FollowMyHealth Partners Ephraim McDowell Health

      by Zacks Equity Research

      Allscripts' (MDRX) FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians.

      Fresenius Medical to Make Huge Investments, Competition Rife

      by Zacks Equity Research

      Fresenius Medical (FMS) is likely to make huge investments in India and China.

      Masimo Gets FDA Clearance for Rad-67 Monitoring Device

      by Zacks Equity Research

      The clearance will enable Masimo (MASI) to provide portable spot-checking monitoring measurements of oxygen saturation and non-invasive hemoglobin.

      Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip

      by Zacks Equity Research

      On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.

      BD Remains Confident About LUTONIX DCB Despite FDA Letter

      by Zacks Equity Research

      Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.

      Senseonics Unveils Eversense Bridge Program in the U.S.

      by Zacks Equity Research

      The Eversense Bridge program aligns with Senseonics' (SENS) strategy of offering innovative yet affordable and hassle-free medical care to diabetic patients.

      Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue

      by Zacks Equity Research

      Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.

      Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

      by Zacks Equity Research

      Sector ETF report for PTH

      Varian (VAR) Scales New 52-Week High on Solid Prospects

      by Zacks Equity Research

      The key growth driving factor for Varian (VAR) in the past year has been increasing net sales from major business segments.

      HMS Holdings Gains on PI & TPM Solutions, Competition Rife

      by Zacks Equity Research

      HMS Holdings is consistently boosting margins and profitability on product-yield enhancements and process improvements.

        Here's Why You Should Retain Ecolab Stock in Your Portfolio

        by Zacks Equity Research

        A solid guidance for 2019 and broad product spectrum will provide Ecolab (ECL) a competitive edge in the MedTech space.